Webdisclosure.com

Search

PHARNEXT (EPA:ALPHA) Pharnext: Data from First Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A, the PLEO-CMT Trial, Published in the Orphanet Journal of Rare Diseases

Directive transparence : information réglementée

18/10/2021 18:01